Lv22
170 积分 2024-04-09 加入
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
2小时前
待确认
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
6小时前
已完结
Risankizumab: First Global Approval
1天前
已完结
Risankizumab: How to choose the right dose in clinical practice?
1天前
已完结
Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety
1个月前
已完结
Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States
1个月前
已完结
Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan
1个月前
已完结
Biosimilars and immunogenicity: a matter of concern?
1个月前
已完结
Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study
1个月前
已完结
Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
1个月前
已关闭
皖公网安备34019202002308
